...
首页> 外文期刊>Arthritis and Rheumatism >Selective blockade of tumor necrosis factor receptor i inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures
【24h】

Selective blockade of tumor necrosis factor receptor i inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures

机译:在人类类风湿关节炎滑膜细胞培养物中选择性阻断肿瘤坏死因子受体i抑制促炎细胞因子和趋化因子的产生

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To determine whether selective blockade of tumor necrosis factor receptor I (TNFRI) affects spontaneous proinflammatory cytokine and chemokine production in ex vivo-cultured human rheumatoid arthritis synovial membrane mononuclear cells (MNCs) and to compare this response to that of TNF ligand blockade using etanercept. Methods A bispecific, single variable-domain antibody (anti-TNFRI moiety plus an albumin binding moiety [TNFRI-AlbudAb]) was used to selectively block TNFRI. Inhibition of TNFα-mediated responses in cell lines expressing TNFRI/II confirmed TNFRI-AlbudAb potency, human rhabdomyosarcoma cell line KYM-1D4 cytotoxicity, and human umbilical vein endothelial cell (HUVEC) vascular cell adhesion molecule 1 (VCAM-1) upregulation. Eighteen RA synovial membrane MNC suspensions were cultured for 2 days or 5 days, either alone or in the presence of TNFRI-AlbudAb, control-AlbudAb, or etanercept. Proinflammatory cytokines and chemokines in culture supernatants were measured by enzyme-linked immunosorbent assays. A mixed-effects statistical analysis model was used to assess the extent of TNFRI selective blockade, where the results were expressed as the percentage change with 95% confidence intervals (95% CIs). Results TNFRI-AlbudAb inhibited TNFα-induced KYM-1D4 cell cytotoxicity (50% inhibition concentration [IC50] 4 nM) and HUVEC VCAM-1 up-regulation (IC50 12 nM) in a dose-dependent manner. In ex vivo-cultured RA synovial membrane MNCs, selective blockade of TNFRI inhibited the production of proinflammatory cytokines and chemokines to levels similar to those obtained with TNF ligand blockade, without inducing cellular toxicity. Changes in cytokine levels were as follows: -23.5% (95% CI -12.4, -33.2 [P = 0.004]) for granulocyte-macrophage colony-stimulating factor, -33.4% (95% CI -20.6, -44.2 [P ≤ 0.0001]) for interleukin-10 (IL-10), -17.6% (95% CI 3.2, -34.2 [P = 0.0880]) for IL-1β, and -19.0% (95% CI -3.4, -32.1 [P = 0.0207]) for IL-6. Changes in chemokine levels were as follows: -34.2% (-14.4, -49.4 [P = 0.0030]) for IL-8, -56.6% (-30.7, -72.9 [P = 0.0011]) for RANTES, and -24.9% (2, -44.8 [P = 0.0656]) for monocyte chemotactic protein 1. Conclusion In ex vivo-cultured RA synovial membrane MNCs, although a limited role of TNFRII cannot be ruled out, TNFRI signaling was found to be the dominant pathway leading to proinflammatory cytokine and chemokine production. Thus, selective blockade of TNFRI could potentially be therapeutically beneficial over TNF ligand blockade by retaining the beneficial TNFRII signaling.
机译:目的确定选择性阻断肿瘤坏死因子受体I(TNFRI)是否影响离体培养的类风湿关节炎滑膜单核细胞(MNCs)的自发促炎细胞因子和趋化因子的产生,并将这种反应与使用依那西普的TNF配体阻断反应进行比较。方法使用双特异性单可变域抗体(抗TNFRI部分加白蛋白结合部分[TNFRI-AlbudAb])选择性地阻断TNFRI。表达TNFRI / II的细胞系中TNFα介导的反应的抑制证实了TNFRI-AlbudAb的效力,人横纹肌肉瘤细胞系KYM-1D4的细胞毒性和人脐静脉内皮细胞(HUVEC)血管细胞粘附分子1(VCAM-1)的上调。将18种RA滑膜MNC悬浮液单独培养或在TNFRI-AlbudAb,对照-AlbudAb或依那西普存在下培养2天或5天。培养上清液中的促炎细胞因子和趋化因子通过酶联免疫吸附测定法进行测量。使用混合效应统计分析模型评估TNFRI选择性阻滞的程度,其中结果表示为具有95%置信区间(95%CI)的百分比变化。结果TNFRI-AlbudAb以剂量依赖的方式抑制TNFα诱导的KYM-1D4细胞毒性(50%抑制浓度[IC50] 4 nM)和HUVEC VCAM-1上调(IC50 12 nM)。在离体培养的RA滑膜MNC中,选择性阻断TNFRI可将促炎性细胞因子和趋化因子的产生抑制到与TNF配体阻断类似的水平,而不会引起细胞毒性。细胞因子水平的变化如下:粒细胞-巨噬细胞集落刺激因子的-23.5%(95%CI -12.4,-33.2 [P = 0.004]),-33.4%(95%CI -20.6,-44.2 [P≤白介素10(IL-10)为0.0001],IL-1β为-17.6%(95%CI 3.2,-34.2 [P = 0.0880])和-19.0%(95%CI -3.4,-32.1 [P] = 0.0207])对于IL-6。趋化因子水平的变化如下:IL-8为-34.2%(-14.4,-49.4 [P = 0.0030]),RANTES为-56.6%(-30.7,-72.9 [P = 0.0011]),和-24.9% (2,-44.8 [P = 0.0656])用于单核细胞趋化蛋白1。结论在离体培养的RA滑膜MNC中,尽管不能排除TNFRII的有限作用,但发现TNFRI信号传导是导致TNFRII的主要途径。促炎细胞因子和趋化因子的产生。因此,通过保留有益的TNFRII信号传导,选择性阻断TNFRI可能比TNF配体阻断在治疗上有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号